Thiazolidinediones (TZDs) act through PPARγ to elicit increased sensitivity to insulin in type 2 diabetes mellitus (T2DM) and reduce inflammation in arteries [1]. This evidence concerns the gene PPARG and type 2 diabetes mellitus.